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Background: Some, but not all, prior investigations suggest armodafinil may have utility as an adjunctive treatment
in bipolar I depression.
Methods: Multicenter, randomized, double-blind study in patients aged 18 to 65 years experiencing a depressive
episode despite maintenance therapy for bipolar I disorder. Patients were randomized to receive adjunctive
armodafinil 150 mg/day or adjunctive placebo for 8 weeks. Primary efficacy outcome was change from baseline in
30-Item Inventory of Depressive Symptomatology–Clinician-Rated (IDS-C30) total score at week 8. Safety and
tolerability were monitored.
Results: Of 656 patients screened, 399 were randomized, of whom 308 (77 %) were taking a protocol-allowed
mood stabilizer as monotherapy. The primary efficacy outcome did not reach statistical significance; however,
several secondary efficacy outcomes demonstrated statistically significant advantages for adjunctive armodafinil
(n = 197) over adjunctive placebo (n = 196), including Clinical Global Impression of Severity of Illness for
depression (weeks 6, 8, and endpoint; all P < 0.05), Global Assessment of Functioning (weeks 4, 8, and endpoint;
all P < 0.02), IDS-C30 remitter rates (week 8 and endpoint; both P < 0.02), and mean change from baseline in
IDS-C30 total score at week 7 (P < 0.05). Adjunctive armodafinil and adjunctive placebo were generally well
tolerated. Although adjunctive armodafinil compared with adjunctive placebo yielded a higher headache rate
(15 vs 8 %), it yielded similar (generally favorably low) rates of all-cause discontinuation (16 vs 16 %), adverse
event discontinuation (4 vs 5 %), nausea (6 vs 4 %), ≥7 % weight gain (2 vs 5 %), anxiety (4 vs 3 %), insomnia
(3 vs 2 %), sedation/somnolence (1 vs 1 %), and hypomania (0 vs <1 %).
Conclusions: In this study, adjunctive armodafinil compared with adjunctive placebo in bipolar I depression did
not separate in the primary efficacy outcome but demonstrated advantages for several secondary efficacy
outcomes and was generally well tolerated. Additional research is warranted and necessary to better identify
clinical predictors (e.g., atypical depressive symptoms, specific anti-manic/mood-stabilizing agents used) that
would provide optimized, individualized therapeutics for bipolar depression.
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Bipolar disorder is a recurrent and debilitating illness
that affects approximately 2.6 % of the adult population
(Kessler et al., 2005), with approximately 1 % of the
population having bipolar I disorder (Merikangas et al.,
2007). Depression is the predominant and prevailing
symptomatic illness phase. For example, in bipolar I
disorder, depression accounts for at least three times
more time ill than mania (Judd et al., 2002; Kupka et al.,
2007). Depressive episodes are associated with more
disability, comorbidity, and functional and occupational
deficits than manic episodes; moreover, the depressive
phase is associated with an increased risk of recurrence
of mood symptoms and rates of suicide (Bauer et al.,
2001; Calabrese et al., 2004; Merikangas et al., 2007;
Merikangas et al., 2011). In clinical settings, adjunctive
treatments may be added to maintenance therapies when
mood symptoms recur, but the clinical evidence base is
limited in this type of therapeutic intervention. Only one
agent, lurasidone, has been approved by the United
States Food and Drug Administration (FDA) as adjunct-
ive treatment, combined with either lithium or valproate
for acute bipolar I depression (Latuda [package insert],
2013). FDA-approved treatments for acute bipolar I de-
pression include the olanzapine/fluoxetine combination,
quetiapine monotherapy, and lurasidone. Investigations
of aripiprazole monotherapy (Thase et al., 2008) and
ziprasidone, as both monotherapy and adjunctive therapy
(Lombardo et al., 2012; Sachs et al., 2011), failed to pro-
vide significant improvements in depressive symptoms
compared with placebo in bipolar I depression. Clearly,
given the morbidity of bipolar depression, more treat-
ment options are needed.
Armodafinil (R-modafinil) is a wakefulness-promoting
low-affinity dopamine transport inhibitor that is currently
approved in the USA for the treatment of excessive sleepi-
ness associated with shift work disorder, narcolepsy, and
obstructive sleep apnea (Nuvigil [package insert], 2013).
Preliminary research on modafinil and armodafinil sug-
gested potential benefit in mood disorders (Calabrese
et al., 2010; Calabrese et al., 2014; Frye et al., 2007).
An initial phase 3 randomized, placebo-controlled
study of adjunctive armodafinil 150 mg/day demon-
strated a significant benefit in bipolar I depression on
the primary outcome (mean change from baseline in
the 30-Item Inventory of Depressive Symptomatology–
Clinician-Rated (IDS-C30) total score) (Rush et al.,
2000) in comparison with placebo (P < 0.01), as well as
some secondary outcomes (Calabrese et al., 2014). In
contrast, a second, similarly designed phase 3 study
found that adjunctive armodafinil 150 mg/day provided
numerically, but not statistically significantly, greater
improvement in bipolar I depression than placebo on
the same primary outcome (Ketter et al., 2015).The current study (ClinicalTrials.gov, study identifier
NCT01305408) was performed to further investigate the
efficacy, safety, and tolerability of adjunctive armodafinil
use in bipolar I depression. As in prior investigations, this
study permitted adjunctive armodafinil or adjunctive pla-
cebo to be combined with a broad array of ongoing bipo-
lar disorder maintenance treatments, in conformity with
the availability of many such choices in clinical practice,
providing the strength of increased generalizability, albeit
with the potential limitation of decreased assay sensitivity.
This study, unlike prior studies, included quetiapine as
one of the permitted maintenance therapies, further con-
tributing to this study’s generalizability and relevance to
clinical practice. As in prior studies, efficacy was assessed
by the mean change from baseline in IDS-C30 total score.Methods
This phase 3, 8-week, randomized, double-blind,
placebo-controlled, parallel-group, fixed-dosage, multi-
center study was conducted at 84 centers in 13 countries
across 4 regions. Patients who were experiencing a
major depressive episode, despite stable doses of
protocol-allowed “mood stabilizers” (lithium and certain
anticonvulsants and antipsychotics) for the treatment of
bipolar I disorder, were randomly assigned to adjunctive
armodafinil 150 mg/day or matching placebo in a 1:1 ra-
tio. The 150-mg dose of armodafinil was selected based
on efficacy and tolerability data from previous clinical
trials. Randomization was stratified on the basis of con-
comitant mood stabilizers being taken (lithium, anticon-
vulsants, and antipsychotics). If a patient was taking
more than one of these medications at randomization, the
patient was assigned to the category of the medication of
longest duration at the discretion of the investigator.
Randomization was also stratified by region of the world
(Region 1, the USA and Canada; Region 2, Armenia,
Azerbaijan, Belarus, Bulgaria, Georgia, Russia, Ukraine,
Kyrgyzstan, Mongolia, Uzbekistan, Albania, Bosnia,
Herzegovina, Croatia, Cyprus, Czech Republic, Greece,
Hungary, Poland, Serbia, Slovakia, Slovenia, Republic of
Macedonia, and Turkey; Region 3, Andorra, Austria,
Australia, Belgium, Denmark, Finland, France, Germany,
Greece, Iceland, Ireland, Italy, Liechtenstein, Luxembourg,
Malta, Monaco, the Netherlands, Norway, Portugal, San
Marino, Spain, Sweden, Switzerland, the UK, and Vatican
City; Region 4, rest of the world).Ethics, consent, and permissions
The study was conducted in accordance with the
International Conference on Harmonisation’s Guideline
for Good Clinical Practice, and the study protocol and
amendments were approved by the independent ethics
committee/institutional review board at each participating
Frye et al. International Journal of Bipolar Disorders  (2015) 3:18 Page 3 of 9center. Written informed consent was obtained from each
patient before screening.
Participants
Inclusion and exclusion criteria were similar to those re-
ported in detail for the previous two studies (Calabrese
et al., 2014; Ketter et al., 2015). Specifically, patients
were aged 18 to 65 years and had bipolar I disorder with
current non-psychotic depression according to the Diag-
nostic and Statistical Manual of Mental Disorders
(Fourth Edition, Text Revision; DSM-IV-TR) criteria
(American Psychiatric Association, 2000), as determined
by the Structured Clinical Interview for DSM-IV, Clin-
ical Trials (SCID-CT) (First et al., 2007). Patients were
required to have had ≥1 previous manic or mixed epi-
sode, which resulted in functional impairment that was
treated (or should have been treated) with a protocol-
allowed mood stabilizer. Patients could not have had >6
mood episodes in the prior year and their current de-
pressive episode must have started ≥2 weeks but
≤12 months prior to the screening visit and occurred
despite taking stable doses of one or two mood stabi-
lizers, defined specifically as lithium, valproate, lamotri-
gine, olanzapine, quetiapine, aripiprazole, risperidone, or
ziprasidone (ziprasidone only in combination with lith-
ium, valproate, or lamotrigine). In patients taking two
mood stabilizers, one was required to be lithium, valpro-
ate, or lamotrigine. Medications known to induce
CYP3A4/5, such as carbamazepine, were not permitted
within 14 days before the baseline visit or during the
study. Furthermore, onset of the current depressive epi-
sode had to be ≥8 weeks after resolution of any previous
mood episode. Concomitant antidepressant use was not
allowed within 14 days or five half-lives before study
entry or during the study. This exclusion was exercised
to minimize the confounding of any effects seen regard-
ing adjunctive drug–placebo differences in bipolar I de-
pressive symptom improvement with armodafinil.
Patients were required to have had screening and base-
line 16-Item Quick Inventory of Depressive Symptomatol-
ogy–Clinician-Rated (QIDS-C16) (Rush et al., 2003) scores
≥13, Clinical Global Impression of Severity of Illness
(CGI-S) for depression score ≥4, Young Mania Rating
Scale (YMRS) (Young et al., 1978) total score ≤10, and
YMRS scores of 0 or 1 on items 1 to 3. Patients were also
required to be in good health based on a physical examin-
ation, electrocardiogram, and laboratory studies.
Patients were excluded if they had other Axis I disor-
ders within 6 months of screening that were the focus
of treatment, or Axis II disorders of concern (border-
line, antisocial, or other personality disorders that could
impact conduct of the study), a history of alcohol or
substance abuse or dependence (with the exception of
nicotine dependence) within 3 months of the screeningvisit or during the screening period, current psychotic
symptoms or psychosis within 4 weeks of screening, ac-
tive suicidal ideation or history of significant suicidal
behaviors, score of ≥2 on item 18 of the IDS-C30,
Hamilton Anxiety Scale (HAM-A) (Hamilton Anxiety
Rating Scale, 2011) total score ≥17 at baseline, or a his-
tory of clinically significant cutaneous drug or hyper-
sensitivity reactions.
Assessments
The primary efficacy assessment was the mean change
from baseline assessed at week 8 in total IDS-C30 score
for adjunctive armodafinil 150 mg/day versus adjunctive
placebo as analyzed by mixed-model repeated measures
(MMRM). Secondary efficacy assessments included
mean change from baseline in the IDS-C30, QIDS-C16,
and CGI-S, as well as IDS-C30 response (≥50 % reduc-
tion from baseline in total score), IDS-C30 remission
(final IDS-C30 score ≤11) rates, and CGI-S response (de-
crease ≥2 points in severity from baseline) rate, all
assessed at weeks 1, 2, 4, 6, 7, and 8 (or early termin-
ation), as well as mean change from baseline in the
Global Assessment of Functioning (GAF), assessed at
weeks 4 and 8, or early termination.
Safety assessments included mean change from baseline
in the YMRS and the Columbia-Suicide Severity Rating
Scale-Since Last Visit (C-SSRS-SLV) (Posner et al., 2009)
at weeks 1, 2, 4, 6, 7, and 8 (or early termination), mean
change from baseline in the HAM-A and Insomnia
Severity Index (ISI) (Bastien et al., 2001) at weeks 4 and 8
(or early termination), as well as collection of adverse
events (AEs) and serious AEs (SAEs), vital signs, and la-
boratory studies.
Statistical analysis
Sample-size calculations were based on IDS-C30 total
score and used estimates of variability obtained from
previous phase 2 and 3 results for armodafinil and mod-
afinil investigations in bipolar I depression (Calabrese
et al., 2010; Calabrese et al., 2014; Frye et al., 2007). Tar-
get enrollment was 370 patients (185 patients for each
of adjunctive armodafinil 150 mg/day and adjunctive
placebo) to ensure that at least 332 patients (166 per
group) were evaluable for efficacy, providing 85 % power
to detect a mean between-group difference of 4 points
in the change from baseline in IDS-C30 total score (as-
suming a standard deviation of 12.1). Data from 393 and
398 patients were analyzed for efficacy and safety,
respectively.
Patients receiving ≥1 dose of study drug were analyzed
for safety (safety analysis set), and patients in the safety
analysis set who had ≥1 post-baseline IDS-C30 efficacy as-
sessment were analyzed for efficacy (full analysis set). For
the primary outcome, IDS-C30 total score was analyzed
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2014). Continuous secondary efficacy variables were ana-
lyzed using analysis of variance and categorical secondary
variables were analyzed by Cochran-Mantel-Haenszel test,
as previously described (Calabrese et al., 2014). Safety and
tolerability were monitored throughout the study.
Results and discussion
Participants
Of the 656 patients with bipolar I depression who were
screened, 399 were enrolled; 200 were randomized to
receive adjunctive armodafinil 150 mg/day and 199
were randomized to receive adjunctive placebo (Fig. 1).
Baseline demographic and clinical characteristics were
statistically similar between treatment groups (Table 1).
The efficacy analysis included a total of 393 patients
(adjunctive armodafinil 150 mg/day, n = 197; adjunctive
placebo, n = 196); the safety analysis set included 398
patients (adjunctive armodafinil 150 mg/day, n = 200;
adjunctive placebo, n = 198). A total of 63 (16 %) pa-
tients withdrew from the study (31 (16 %) receiving ad-
junctive armodafinil and 32 (16 %) receiving adjunctive
placebo). At baseline, most patients (n = 308, 77 %)
were taking only one mood stabilizer/antipsychotic.
Valproate, lamotrigine, and risperidone were the most
common mood stabilizer/antipsychotic treatments
taken as monotherapy (Table 2). At baseline, depression
scores were consistent with moderate to severe depres-
sion and were statistically similar between treatment
groups.
A total of 17 patients discontinued early due to AEs
(adjunctive armodafinil 150 mg/day, 7/200 (4 %);
adjunctive placebo, 10/199 (5 %)). Anxiety and bipolar I
disorder were the only AEs that caused discontinuation
in >1 patient; anxiety led to treatment discontinuation
in 3 (2 %) of those treated with adjunctive armodafinilFig. 1 Patient flowand 0 treated with adjunctive placebo; 2 patients taking
adjunctive armodafinil and 0 patients taking adjunctive
placebo discontinued due to bipolar I disorder.Efficacy
Primary efficacy
Baseline mean IDS-C30 scores were 42.4 in the adjunct-
ive armodafinil group and 43.3 in the adjunctive placebo
group. The least-square (LS) mean and standard error of
the LS mean (SEM) change from baseline to week 8 on
the IDS-C30 (primary efficacy parameter) for armodafinil
versus placebo (−20.8 ± 0.99 vs −19.4 ± 0.99) in the ad-
junctive treatment of bipolar I depression was not statis-
tically significant (P = 0.27).Secondary efficacy
Although not adjusted for multiple comparisons, sev-
eral secondary efficacy outcomes suggested advantages
in favor of adjunctive armodafinil (Table 3). Specific-
ally, statistically significant differences for the IDS-C30
secondary variables in favor of adjunctive armodafinil
150 mg/day over adjunctive placebo included proportion
of IDS-C30 responders at week 6 (41 vs 29 %, P = 0.018),
week 7 (51 vs 39 %, P = 0.015), and week 8 (56 vs
46 %, P = 0.039) (Fig. 2, left); proportion of IDS-C30 re-
mitters at week 8 (26 vs 15 %, P = 0.011) and endpoint
(22 vs 13 %, P = 0.011) (Fig. 2, right); and mean change
from baseline in IDS-C30 total score at week 7 (P < 0.05).
In addition, statistically significant differences in favor of
adjunctive armodafinil were observed for the mean change
from baseline in CGI-S rating for depression at week 6
(P < 0.03), week 8 (P < 0.02), and endpoint (P < 0.04)
and in mean change from baseline in GAF scores, indi-
cating improvement in patient functioning, at week 4
(P < 0.02), week 8 (P < 0.002), and endpoint (P < 0.01).





Age, years, mean (SD) 43.7 (11.6) 45.3 (11.3)
Males, n (%) 78 (39) 80 (40)
Race, n (%)
White 176 (88) 182 (91)
Black 16 (8) 14 (7)
Other 7 (4) 4 (2)
Weight, kg, mean (SD) 81.2 (17.5) 80.7 (17.5)
IDS-C30 total score, mean (SD) 43.3 (7.7) 42.4 (7.7)
QIDS-C16 total score, mean (SD) 16.8 (2.7) 16.1 (2.7)
CGI-S score, mean (SD) 4.6 (0.6) 4.6 (0.7)
GAF score, mean (SD) 54.8 (6.7) 53.6 (8.9)
C-SSRS
Suicidal behavior, n (%)
Suicidal behavior, actual attempt 20 (10) 21 (11)
Non-suicidal self-injurious
behavior
7 (4) 6 (3)
Interrupted attempt 3 (2) 2 (1)
Aborted attempt 4 (2) 4 (2)
Suicidal behavior 4 (2) 4 (2)
Preparatory acts or behavior 5 (3) 6 (3)
Suicidal ideation, n (%)
Suicidal ideation, wish to be dead 27 (14) 37 (19)
Non-specific active suicidal
thoughts
16 (8) 24 (12)
Any methods (no plan) without
intent to act
12 (6) 20 (10)
Some intent to act without
specific plan
9 (5) 14 (7)
Specific plan and intent 10 (5) 15 (8)
YMRS total score, mean (SD) 3.7 (2.1) 3.7 (2.2)
HAM-A total score, mean (SD) 12.6 (2.8) 12.5 (2.9)
ISI total score, mean (SD) 16.1 (5.2) 15.7 (5.5)
CGI-S Clinical Global Impression of Severity of Illness, C-SSRS-SLV Columbia-
Suicide Severity Rating Scale-Since Last Visit, GAF Global Assessment of
Functioning, HAM-A Hamilton Anxiety Scale, IDS-C30 30-Item Inventory of
Depressive Symptomatology–Clinician-Rated, ISI Insomnia Severity Index,
QIDS-C16 16-Item Quick Inventory of Depressive Symptomatology–Clinician-
Rated, SD standard deviation, YMRS Young Mania Rating Scale
Table 2 Concomitant mood stabilizers






Patients taking one mood stabilizer 150 (75) 158 (79)
Aripiprazole 16 (8) 9 (5)
Lamotrigine 26 (13) 28 (14)
Lithium 12 (6) 18 (9)
Olanzapine 23 (12) 25 (13)
Quetiapine 18 (9) 26 (13)
Risperidone 29 (15) 24 (12)
Valproic acid 26 (13) 28 (14)
Patients taking two mood stabilizers 45 (23) 38 (19)
Aripiprazole + lamotrigine 4 (2) 1 (<1)
Lamotrigine + quetiapine 7 (4) 1 (<1)
Lamotrigine + ziprasidone 1 (<1) 1 (<1)
Lithium + aripiprazole 1 (<1) 0
Lithium + lamotrigine 3 (2) 2 (1)
Lithium + olanzapine 2 (1) 0
Lithium + quetiapine 4 (2) 3 (2)
Lithium + risperidone 1 (<1) 1 (<1)
Lithium + valproic acid 2 (1) 1 (<1)
Lithium + ziprasidone 3 (2) 1 (<1)
Olanzapine + lamotrigine 1 (<1) 1 (<1)
Olanzapine + quetiapine 1 (<1) 0
Valproic acid + aripiprazole 0 2 (1)
Valproic acid + lamotrigine 2 (1) 0
Valproic acid + olanzapine 5 (3) 8 (4)
Valproic acid + quetiapine 5 (3) 9 (5)
Valproic acid + risperidone 3 (2) 5 (3)
Valproic acid + ziprasidone 0 2 (1)
Patients taking three mood
stabilizers
1 (<1) 3 (2)
Lithium + lamotrigine +
ziprasidone
0 1 (<1)
Valproic acid + aripiprazole +
risperidone
0 1 (<1)
Valproic acid + olanzapine +
lamotrigine
0 1 (<1)
Valproic acid + risperidone +
quetiapine
1 (<1) 0
Patients with mood stabilizer
unknown
3 (2) 1 (<1)
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findings favoring adjunctive armodafinil versus adjunctive
placebo on the LS mean ± SEM change from baseline to
endpoint in IDS-C30 total score (−18.2 ± 1.23 vs −17.1 ±
1.23), QIDS-C16 total score (−7.1 ± 0.49 vs −7.0 ± 0.49),
and IDS-C30 response at endpoint (49 vs 41 %). There
were no statistically significant differences between groups
in the proportion of CGI-S responders at any assessment
point.Safety
Adjunctive armodafinil 150 mg/day in bipolar I depression
was generally well tolerated. Overall, 89 (45 %) patients re-
ceiving adjunctive armodafinil and 71 (36 %) patients re-
ceiving adjunctive placebo experienced ≥1 AE. Of these,
53 (27 %) AEs with adjunctive armodafinil and 32 (16 %)
with adjunctive placebo were considered treatment-
Table 3 Secondary efficacy parameters, full analysis set





LSM change from baseline in IDS-C30 total score
Week 1 −6.1 −5.5 0.3025
Week 2 −10.4 −9.3 0.1940
Week 4 −12.3 −12.5 0.8481
Week 6 −14.2 −16.1 0.0926
Week 7* −16.0 −18.3 0.0492
Week 8 −17.7 −19.6 0.1174
Endpoint −18.3 −19.5 0.3526
LSM change from baseline in QIDS-C16 total score
Week 1 −2.6 −2.4 0.3858
Week 2* −4.5 −3.8 0.0387
Week 4 −5.2 −5.2 0.9978
Week 6 −6.0 −6.5 0.3024
Week 7 −6.7 −7.4 0.1530
Week 8 −7.4 −7.7 0.5471
Endpoint −7.0 −7.1 0.7626
LSM change from baseline in CGI-S score
Week 1 −0.2 −0.2 0.4497
Week 2 −0.5 −0.5 0.9625
Week 4 −0.7 −0.8 0.1467
Week 6* −0.9 −1.2 0.0226
Week 7 −1.1 −1.3 0.0757
Week 8* −1.2 −1.5 0.0159
Endpoint* −1.1 −1.3 0.0320
Proportion of CGI-S responders, n (%)a
Week 1 4 (2) 4 (2) 0.9939
Week 2 15 (8) 16 (8) 0.8927
Week 4 28 (15) 36 (20) 0.2585
Week 6 44 (26) 56 (33) 0.1350
Week 7 55 (32) 68 (40) 0.1031
Week 8 66 (40) 84 (50) 0.0516
Endpoint 67 (34) 86 (44) 0.0503
Week 4* 5.3 7.7 0.0113
Week 8** 11.4 15.2 0.0012
Endpoint** 10.4 13.5 0.0066
CGI-S Clinical Global Impression of Severity of Illness, GAF Global Assessment
of Functioning, IDS-C30 30-Item Inventory of Depressive Symptomatology–Clin-
ician-Rated, LSM least-square mean, QIDS-C16 16-Item Quick Inventory of
Depressive Symptomatology–Clinician-Rated *P<0.05. **P<0.01.
aThe denominator for calculating the percentages at each visit is the
number of patients with a non-missing value at that visit. A responder is a
patient with a decrease of at least 2 points in severity from baseline in CGI-S
rating for depression. The P value for the treatment comparison is from a
Cochran-Mantel-Haenszel test, stratified by concurrent mood-stabilizing
medication and region of the world
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in either treatment group: headache in 29 (15 %) with ad-
junctive armodafinil vs 15 (8 %) with adjunctive placebo
and nausea in 12 (6 %) with adjunctive armodafinil vs 7
(4 %) with adjunctive placebo. The majority of AEs were
mild (in 53 (27 %) vs 47 (24 %)) or moderate (in 32 (16 %)
vs 20 (10 %)) in severity for adjunctive armodafinil vs ad-
junctive placebo, respectively.
Rates of AEs causing withdrawals and incidences of SAEs
were similar between groups. Withdrawals due to AEs oc-
curred in 7 (4 %) patients taking adjunctive armodafinil and
10 (5 %) patients taking adjunctive placebo. Serious AEs oc-
curred in 5 (3 %) patients taking adjunctive armodafinil and
6 (3 %) patients taking adjunctive placebo; no single SAE
occurred in >1 patient. No deaths occurred in either treat-
ment group. At study endpoint, there were no clinically sig-
nificant differences in mean changes from baseline in
serum chemistries, lipid profiles, and hematologic or urin-
alysis parameters noted between the two treatment groups.
There were no clinically significant changes in vital signs or
electrocardiograms in either treatment group.
There were few changes from baseline to endpoint in sui-
cidal ideation and behavior as assessed by C-SSRS-SLV. In
the adjunctive armodafinil group, 1 patient had an SAE
coded using the Medical Dictionary for Regulatory Activ-
ities preferred term of “bipolar I disorder” (specifically,
exacerbation of bipolar disorder (mixed episode with
psychotic symptoms)), accompanied by a suicide attempt,
with no substantive threat to life; both SAEs resolved with
no residual effect. One patient taking adjunctive placebo
had an SAE of suicidal ideation, which resolved without
any sequelae.
Mean changes in YMRS, HAM-A, and ISI total scores
from baseline to endpoint were statistically similar with ad-
junctive armodafinil vs adjunctive placebo, respectively, as
follows: YMRS (−0.9 vs −1.0), HAM-A (−4.3 vs −4.2), and
ISI (−7.1 vs −7.0).
The following AE rate differences were observed be-
tween adjunctive armodafinil and adjunctive placebo, re-
spectively: emergence of hypomania (0 (0 %) vs 1 (<1 %)),
anxiety (8 (4 %) vs 5 (3 %)), insomnia (6 (3 %) vs 4 (2 %)),
sedation/somnolence (2 (1 %) vs 2 (1 %)), and ≥7 % weight
gain (4 (2 %) vs 9 (5 %)).Discussion
There is a compelling need for effective, well-tolerated
treatments for bipolar I depression, for use adjunctively
or as monotherapy. Despite the clinical practice of add-
ing adjunctive treatments to ongoing maintenance
medications when an episode of bipolar I depression
emerges, there is little adequately controlled evidence
to inform such clinical decisions. In fact, only one
agent, lurasidone, has been approved by the FDA for
Fig. 2 IDS-C30 response and remission. IDS-C30 = 30-Item Inventory of Depressive Symptomatology–Clinician-Rated
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bipolar I depression (Latuda [package insert], 2013).
A phase 2 study (Calabrese et al., 2010) and two subse-
quent phase 3 studies (Calabrese et al., 2014; Ketter
et al., 2015) previously evaluated the efficacy and safety
of adjunctive armodafinil treatment for depressive symp-
toms in bipolar I disorder, both using the same primary
efficacy measure (IDS-C30). Conflicting findings from
the first two phase 3 studies warranted additional re-
search. In the current study, the adjunctive use of armo-
dafinil 150 mg/day for bipolar I depression provided a
numerical but nonsignificant difference vs placebo on
the primary outcome (reduction of depressive symptom-
atology as measured by the IDS-C30 total score). The
negative primary outcome result of this study was simi-
lar to that of the similarly designed second phase 3 study
(Ketter et al., 2015) and did not support or confirm the
statistically significant primary outcome finding from the
initial phase 3 study (Calabrese et al., 2014). However, in
the current study (like the first study and unlike the sec-
ond study), adjunctive armodafinil 150 mg/day com-
pared with placebo yielded statistically significant
benefits for several secondary outcomes, including the
proportion of IDS-C30 responders at weeks 6, 7, and 8,
proportion of IDS-C30 remitters at week 8 and endpoint,
and mean change from baseline in IDS-C30 total score at
week 7. In addition, mean change from baseline in the
CGI-S rating for depression (indicating improvement in
depressive symptomatology) was statistically significant
at weeks 6 and 8, and at endpoint, and mean change
from baseline in the GAF score (indicating improvement
in patient functioning) was statistically significant at
weeks 4 and 8, and at endpoint. In all 3 studies,adjunctive armodafinil was consistently well tolerated,
with no clinically relevant differences vs adjunctive pla-
cebo for the emergence of hypomania, insomnia, anx-
iety, sedation/somnolence, or ≥7 % weight gain.
Some patients with bipolar disorder may be candi-
dates for combination therapy to manage manic, hypo-
manic, mixed, depressed, and/or cycling related mood
symptoms. In contrast to most regulatory non-
monotherapy bipolar disorder clinical trials, which limit
adjunctive treatments to lithium, valproate, and only
very recently lamotrigine or one atypical antipsychotic,
this study allowed 29 different combinations of mood-
stabilizing treatments prior to study randomization (see
Table 2). The assay sensitivity (i.e., drug–placebo separ-
ation) of this study was potentially limited by what was
identified a priori as a study design strength (i.e., poten-
tial generalizability and community translation). A sec-
ond challenge overall is the design of a study for a
novel compound that is not considered a “mood
stabilizer” where the trial design template has conven-
tionally been designed for atypical antipsychotic mood
stabilizers (i.e., lurasidone, olanzapine/fluoxetine, and
quetiapine).
Conclusions
In this 8-week study marked by significant therapeutic
heterogeneity, adjunctive armodafinil 150 mg/day
yielded a numerically greater, but not statistically signifi-
cant, improvement on the primary efficacy outcome
measure compared with placebo in treatment of bipolar
I depression. Several secondary outcomes favoring armo-
dafinil at endpoint, including a significantly higher re-
mission rate, and paralleled by significant global and
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indicate that adjunctive armodafinil provided a reduction
of depressive symptoms in a subset of patients with bi-
polar I depression vs placebo. Adjunctive armodafinil
was generally well tolerated in this study, with rates of
anxiety, insomnia, sedation/somnolence, and weight gain
similar to those observed with adjunctive placebo.
This investigation adds to the evidence from two prior
phase 3 studies of similar design, in which armodafinil
150 mg/day, adjunctive to protocol-allowed mood stabi-
lizers, provided statistically significant improvement in
at least some measures of depressive symptoms associ-
ated with bipolar I disorder (Study 3071; NCT01072929
and Study 3072; NCT01072630) (Calabrese et al. 2014;
Ketter et al. 2015). Although armodafinil was generally
well tolerated in this and prior phase 3 studies, the lack
of statistically significant efficacy on the primary out-
come in two of three studies has led to the discontinu-
ation of the development program for adjunctive
armodafinil in bipolar I depression. Additional research
is warranted and necessary to better identify clinical pre-
dictors (e.g., atypical depressive symptoms, specific com-
binations of therapeutic agents) that would provide
optimized and individualized therapeutics for bipolar
depression.
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